Skip to main content
. 2015 Nov 26;7(3):2921–2935. doi: 10.18632/oncotarget.6404

Figure 3. Specific knockdown of erbB3, but not IGF-1R, re-sensitizes the trastzumab-resistant breast cancer cells to lapatinib-mediated growth inhibition.

Figure 3

SKBR3-Pool2 and BT474-HR20 cells infected with lentivirus containing either ConshRNA or erbB3shRNA/1RshRNA were plated onto 96-well plates. After 24 hr, the culture medium was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing the indicated concentrations of lapatinib for another 72 hr. The percentages of surviving cells from each cell line relative to controls, defined as 100% survival, were determined by reduction of MTS. Bars, SD. Data show a representative of three independent experiments.